Adam Schechter, Labcorp CEO
July 28, 2022 07:06 AM EDTUpdated 11:05 AM
Deals
Manufacturing

Lab­corp is spin­ning out its clin­i­cal de­vel­op­ment unit in ma­jor shake­up

Max Gelman

Senior Editor

Tyler Patchen

News Reporter

Lab­corp an­nounced this morn­ing that it is spin­ning out most of its CRO busi­ness, eight years af­ter its $6 bil­lion Co­v­ance ac­qui­si­tion.

Lab­corp will keep …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

A service from the Financial Times